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Abstract: Consumption of cruciferous vegetables has been associated with a reduced risk 
in the development of various types of cancer. This has been attributed to the bioactive 
hydrolysis products that are derived from these vegetables, namely isothiocyanates. Erucin 
is  one  such  product  derived  from  rocket  salads,  which  is  structurally  related  to 
sulforaphane, a well-studied broccoli-derived isothiocyanate. In this review, we present 
current knowledge on mechanisms of action of erucin in chemoprevention obtained from 
cell and animal models and relate it to other isothiocyanates. These mechanisms include 
modulation of phase I, II and III detoxification, regulation of cell growth by induction of 
apoptosis and cell cycle arrest, induction of ROS-mechanisms and regulation androgen 
receptor pathways. 
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1. Introduction 
The recent report by the World Cancer Research Fund (WCRF) International together with the 
American Institute of Cancer Research (AICR) underlined that cancer is 30%–40% preventable over 
time by appropriate food and nutrition [1]. A significant part of the research on plant foods and cancer 
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prevention suggests the potentially beneficial effect of a diet rich in cruciferous vegetables [2–11]. At 
present,  the  putative  role  of  cruciferous  vegetables  on  cancer  chemoprevention  is  related  to  the 
bioactivity of the glucosinolate (GLS) hydrolysis products, namely isothiocyanates (ITCs), suggested 
to  protect  against  the  most  common  cancer  types,  such  as  lung,  prostate,  breast  and  colon  cancers  
[12–22]. Among cruciferous vegetables, rocket salads are widely used in the Mediterranean diet and 
are well-studied as source of healthy phytochemicals [23,24]. The name “rocket” is commonly used to 
indicate different species belonging to the large family of Brassicaceae that are mainly represented by  
Eruca  sativa  Mill.  (also  known  as  salad  rocket)  and  Diplotaxis  tenuifolia  L.  (wild  rocket).  Both, 
largely distributed in the Mediterranean area, have gradually spread to other latitudes, and are used for 
their pungent flavor as new ingredients in green leafy salads [25].
 In the last decade, salad species 
consumption  has  become  increasingly  important  worldwide,  encouraged  from  the  positive  link 
between eating fresh raw materials and absorption of health-promoting phytochemicals. It has been 
shown that the overall average bioavailability of ITCs is 61% and 10% for raw and cooked cruciferous 
vegetables, respectively [26]. In terms of antioxidant compounds, rocket salad species are a good 
source of vitamins, like vitamin C, carotenoids, and polyphenols, which play a very important role 
among natural antioxidants [27]. Moreover, they are characterized by high GLS content, such as other 
cruciferous  vegetables,  and  their  enzymatic  degradation  products  are  not  only  responsible  for  the 
typical sensory properties of these cruciferous salads, but also of their potentially beneficial effects on 
human  health  [28].  The  4-(methylthio)  butyl  isothiocyanate  (erucin  or  ER)  has  been  previously 
identified as a major component derived from rocket salad leaves [29,30], able to affect selectively 
cancer cell growth [31,32]. In this review, we attempt to provide an overview of the biological profile 
of  this  new  cancer  chemopreventive  phytochemical,  underlying  its  pharmacokinetic  and 
pharmacodynamic properties.  
2. Pharmacokinetic and Bioavailability of ER  
The isothiocyanate ER is obtained from enzymatic hydrolysis of glucoerucin, isolated for the first 
time in the 1970s from seeds of Eruca sativa Mill. and overall found at high levels in rocket salad 
species, but also through reduction in vivo of the isothiocyanate sulforaphane (SF), that structurally 
represents its oxidized analog, characteristic of broccoli (Brassica oleracea L. ssp. italica) [33–35] 
(Figure 1).  
The bioavailability of ER has not been studied to date. However, ER and SF are structurally related: 
both  have  an  aliphatic  side  chain  that  could  support  a  similar  pharmacokinetic  fate.  SF,  such  
as  other  ITCs,  is  initially  subjected  to  enzymatic  conjugation  in  vivo  with  the  tripeptide  
γ-glutamylcysteineglycine (GSH) that is catalyzed by glutathione transferases (GSTs) [36]. The rate, 
however, of the enzymatic reaction of ITCs with GSTs was found to differ between structurally closely 
compounds. Among naturally occurring ITCs that differ only in the oxidation state of the sulfur atom 
that  is  inserted  into  the  carbon  chain,  SF  appears  to  be  the  poorest  substrate  for  all  four  GST 
isoenzymes;  in  contrast,  ER  seems  to  be  the  best,  thus  its  conjugation  with  GSH  occurs  faster 
compared  to  the  reduced  analog  SF  [37].  After  conjugation  with  GSH,  ITCs  are  principally 
metabolized by the mercapturic acid pathway. Mercapturic acids excreted in urine can be used to 
determine the bioavailability of ITCs, because their excretion in urine reflects the intake of GLSs, thus Toxins 2010, 2                         
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the corresponding uptake of ITCs, after cruciferous vegetables consumption [38]. It has been recently 
reported that ER and SF mercapturic acids are excreted in urine with high excretion levels after four 
hours following consumption of rocket salads (average bioavailability ≈ 94%) [26]. These data have 
underlined the same in vivo kinetics of these structurally related ITCs, showing similar absorption rate 
(ER ka = 2.5 h
−1, SF ka = 2.0 h
−1) and excretion rate (ER ka = 0.24 h
−1, SF ka = 0.19 h
−1) constants after 
rocket salad consumption. Interestingly, the excretion in urine of ER mercapturic acid has been also 
reported after consumption of cruciferous vegetables, such as broccoli and red and white cabbage that 
do not contain glucoerucin (<0.01 mmol/kg) [26]. After consumption of raw broccoli, not containing 
glucoerucin, both ER and SF mercapturic acids were found in urine samples after four hours with 29% 
and  50%  excretion  levels,  respectively,  where  the  level  of  excretion  of  ER  mercapturic  acid  was 
expressed as % of the dose of glucoraphanin (the parent GLS of SF). These finding have shown for the 
first time the metabolic interconversion of SF to ER in humans. Previously, this metabolic reaction has 
been  demonstrated  in  rats,  where  ER  appears  to  be  a  major  metabolic  product  of  SF  [35,39]. 
Approximately 12% of a single dose of SF, following intraperitoneal (ip) administration in rats, was 
eliminated in the urine (after 24 h) as N-acetylcysteine (NAC) conjugates of ER, and 67% of a single 
dose  of  ER  was  eliminated  as  conjugates  of  SF.  These  experimental  data  have  assessed  the 
reversibility of the oxidation-reduction biotransformation of the sulfur atom in ER and SF, showing 
that the oxidation of the sulfide in ER was a more favored metabolic reaction compare to the reduction 
of the sulfoxide in SF  [35]. Moreover, the reduction  in vivo of SF to ER has been demonstrated 
following  oral  administration  of  SF  in  rats,  supporting  the  previous  finding  of  intraperitoneal 
administration  in  rats  [39].  Despite  an  insufficient  direct  knowledge  of  the  metabolism  of  ER  in 
humans, the in vivo interconversion of ER in SF and their structural similarity support the hypothesis 
about a similar metabolic fate. Thiol-conjugates of SF (thiol-SF) are the major metabolic products 
formed via mercapturic acid pathway in humans [38]. The conjugation of SF with thiols is a reversible 
reaction, and SF release by deconjugation reactions occurs in plasma and tissues under physiological 
conditions [40] and has been measured following broccoli consumption [41,42]. For this reason, the 
chemopreventive  activity  of both  free  SF and  thiol-SF has been previously studied  in vitro using 
different cancer cell lines, to reinforce the in vivo observation that SF and its metabolic products 
inhibit  the  progression  of  human  cancer  [43].  At  present,  the  biological  activity  of  ER  has  been 
investigated in various human cell lines, but there are no studies showing a similar in vitro bioactivity 
of its metabolic products. 
3. Bioactivity of Rocket salad Species 
Rocket  species  are  well-known  in  traditional  medicine  for  their  therapeutic  properties  as  an 
astringent, diuretic, digestive, emollient, tonic, depurative, laxative, rubefacient and stimulant [44–47]. 
It  has  been  suggested  that  Eruca  sativa  seeds  exert  a  beneficial  antidiabetic  effect  in  cases  of 
chemically induced diabetes mellitus in rats by reducing oxidative stress [48]. Eruca s. extracts have 
also  been  shown  to  have  a  significant  protective  effect  against  HgCl2-induced  nephrotoxicity  in  
rats  [49].  In  both  mentioned  studies,  the  health-promoting  activities  of  rockets  plants  have  been 
partially related to their strong antioxidant properties [50–52]. Recently, anti-ulcer properties of rocket 
salads  on  experimentally-induced  gastric  secretion  and  ulceration  in  albino  rats  have  been Toxins 2010, 2                         
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demonstrated [53]. In a study carried out by Lamy and colleagues there is evidence of the strong 
antigenotoxic  effect  of  Eruca  s.  in  benzo[a]pyrene  exposed  human  hepatoma  (HepG2)  cells  [54]. 
Recently, chemoprotective properties of rocket leaves on human colon cancer cells have been also 
investigated [55] (Table 1). 
Figure 1. The 4-(methylthio)butyl isothiocyanate, erucin (ER), is a reduced analog of the 
4-(methylsulfinyl)butyl  isothiocyanate,  sulforaphane  (SF),  and  its  formed  both  from 
enzymatic hydrolysis of glucoerucin, a glucosinolate found at high levels in rocket species 
(Eruca sativa Mill., Diplotaxis tenuifolia L.) and in vivo reduction of SF, derived from 
broccoli (Brassica oleracea L. ssp italica). 
 
Table 1. Experimental evidence supporting health promoting activity of rocket salad species. 
Rocket species   Health promoting activity   Experimental Model   Reference  
Eruca sativa (seeds)   antidiabetic activity   rats   [48]  
Eruca sativa (seeds)  
 
protective effect against 
HgCl2-induced nephrotoxicity  
rats   [49]  
Eruca sativa (seeds, 
sprouts) 
Eruca sativa (leaves)  
Eruca sativa (leaves)  
antioxidant activity   in vitro assays   [50]  
 
[51] 
[52]  
Eruca sativa (leaves)   anti- ulcer activity   albino rats   [53]  
Eruca sativa  
 
 
antigenotoxic activity   human hepatocellular 
carcinoma HepG2 cell 
line  
[77]  
Eruca sativa (leaves) 
Diplotaxis tenuifolia 
(leaves)  
chemopreventive activity   human colonic cancer 
HT-29 cell line  
[55]  Toxins 2010, 2                         
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4. Cancer Chemoprevention and Treatment with ER: Evidence from Cell and Animal Research 
ER has demonstrated promising anticancer effects in various in vitro and in vivo studies. Zhang and 
colleagues have shown for the first time the protective effects of ER against cancer through induction 
of  detoxification  enzymes  in  several  mouse  tissues  [56].  These  findings  have  been  consequently 
confirmed in other rat and human tissues and in human cancer cells [57–62]. The effects of ER on 
growth inhibition, cell cycle regulation, and apoptosis induction in prostate, lung, liver and colon 
cancer systems have also been reported [31,54,62,63]. Cell cycle arrest, apoptosis and mitochondrial 
potential depolarization by ER was shown in human leukaemia cells and their multidrug resistance 
variants [64]. Moreover, ER can be considered a naturally occurring ITC able to affect selectively 
cancer  cell  growth,  as  shown  in  human  leukemia  cells.  Fimognari  and  colleagues  have  provided 
evidence that ER is able to induce a strong antiproliferative effect on human leukemia cells, but not in 
non-transformed human peripheral T lymphocytes [32]. In a number of studies ER has been shown to 
share similar biological activity with SF [50,58,59,62,64], however SF seems to inhibit the growth of 
both transformed and non-transformed human peripheral T lymphocytes [65]. Although the phenyl 
ethyl isothiocyanate (PEITC) has exhibited selectivity for oncogenically transformed ovarian epithelial 
cells [66], ITC selectivity is an area of great interest that warrants further investigation. 
5. Molecular Mechanisms of Cancer Chemoprevention by ER 
Our understanding of the mechanisms by which bioactive food components may prevent cancer is 
of primary importance for the translation of laboratory findings to clinical approaches. It is becoming 
increasingly  clear  that  many  dietary  agents,  such  as  ITCs,  can  retard  or  prevent  the  process  of 
carcinogenesis by multiple mechanisms perturbing the three major steps, initiation, promotion and 
progression, as well as the later stages, angiogenesis and metastasis (Figure 2).  
Figure 2. Molecular mechanisms of chemoprevention by ITCs, mainly determined through 
work on sulforaphane, an ITC related to erucin. 
 Toxins 2010, 2                         
 
 
598 
The in vivo interconversion of ER to its structurally related analog SF and their structural similarity 
has  suggested  a  similar  biological  activity.  Since  the  early  1960s,  when  SF  was  discovered,  its 
biological activity and molecular targets have been widely investigated in vitro and in vivo [36]. The 
growing body of cell and animal research has contributed to a comprehensive biological profile of SF 
by  underlying  several  modes  of  action  for  its  anticarcinogenic  activity,  such  as  enhancement  of 
detoxification  of  human  carcinogens  through  induction  of  phase  II  drug  metabolizing  enzymes, 
reduction  of  carcinogen  activation  through  suppression  of  cytochrome  P450-dependent 
monooxygenases, promotion of apoptosis in cancer cells, perturbation in cell cycle progression and 
inhibition of angiogenesis and metastasis [36]. At present, literature data suggest that ER may also 
exert its potential protective effects against human cancer through similar multiple mechanisms that 
will be summarized in the following subsections (Table 2). 
Table 2. Chemopreventive effects of ER and its molecular targets in vitro and in vivo assays. 
Biological activity   Molecular targets   Experimental model   Reference  
Modulation of Phase I 
enzymes 
CYP540 isoforms 
human hepatocellular carcinoma 
HepG2 cell line  
ex vivo rat and human tissues 
[77] 
 
[57,58]  
Induction of Phase II 
enzymes 
quinone reductase (QR) 
glutatione transferase 
(GST) 
mouse tissues 
human tissues 
human colonic cancer CACO-2 cells 
rat and human tissues 
[56] 
[61] 
[62] 
[59] 
Up- regulation of Phase 
III detoxification system 
multidrug resistance 
proteins (MRP- 1 and 2) 
human colonic cancer CACO-2 cells 
human cancer cell lines (HepG2, 
CACO-2, A549)  
[61] 
[91]  
Modulation of cell 
proliferation 
tumour suppressor 
proteins (p53, p21) 
human lung adenocarcinoma A549 cells 
human hepatocellular carcinoma 
HepG2 cells  
[31]  
[54] 
Cell cycle checkpoints 
human colonic cancer CACO-2 cells 
human leukemia cells 
 
[61] 
[64] 
[32] 
pro- apoptotic signals 
human colonic cancer CACO-2 cells 
human leukemia cells 
 
human hepatocellular carcinoma 
HepG2 cells 
[61] 
[64] 
[32] 
[54] 
androgen receptor (AR)  human prostate cancer LNCaP cell line   [63] 
reactive oxygen species 
(ROS) 
human acute myeloid leukaemia HL60 
and erythroblastic chronic myelogenous 
leukemia K562 cell lines  
[105] 
 
To determine biological activity using in vitro and in vivo systems, it is essential to know the levels 
of ITCs achieved in systemic circulation following consumption of cruciferous vegetables. Although 
currently there is no evidence for ER and its metabolites in human plasma, there is evidence that SF 
and its metabolites circulate in the plasma of volunteers at a maximum concentration of 2.2 µ M at  Toxins 2010, 2                         
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1.5 hours after consumption of one portion of broccoli, of which more than 40% was measured to be free 
SF [42]. This suggests that care should be exercised when extrapolating from cell studies where typical 
concentrations are several fold higher than those obtained through dietary consumption. However, it is 
likely that tissues of the upper gastrointestinal tract will be exposed to concentrations higher than other 
tissues that rely on systemic circulation. Yet, it is also conceivable that in those latter tissues ITCs could 
accumulate, thereby increasing concentrations above those found in systemic circulation. 
5.1. Effects of ER on xenobiotic metabolism processes 
The human metabolism is a major component of the physiological  defense response to a large 
number of xenobiotics, including human carcinogens. Lipophilic compounds are converted to water 
soluble  and  readily  excretable  metabolites  by  enzymatic  biotransformation  reactions  involving  an 
initial introduction of functional groups (phase I) and the subsequent conjugation of such functional 
groups  with  endogenous  polar  molecules  (phase  II).  The  final  excretion  of  xenobiotics  and  their 
metabolites is mediated by phase III transporters, which are subjected, as phase I and II enzymes, to 
regulatory mechanisms of both induction and inhibition. Several studies have identified the correlation 
between expression of various metabolizing enzymes with risk of different cancer types, highlighting 
the  role  of  xenobiotic  metabolic  enzymes  on  carcinogenesis  [67].  Many  dietary  compounds  can 
directly activate or inhibit these enzymes perturbing xenobiotic metabolism [68].  
Although  SF  has  been  shown  to  inhibit,  directly  or  via  a  competitive  mechanism,  expression  
and  activity  of  various  phase  I  cytochrome  P450  (CYP450)  enzyme  isoforms  in  rat  and  human  
tissues [69–76], phase I enzyme inhibition by ER has not been demonstrated to date. ER (5–20 μM) 
did not inhibit CYP1A1 protein expression in HepG2 cells after exposure to the human carcinogen 
benzo[a]pyrene  (BaP  50  μM),  although  ER  reduced  the  BaP-induced  CYP1A1  activity  in  a  
dose-dependent  manner  reaching  25%  inhibition  at  the  highest  concentration  tested.  Moreover, 
exposure of HepG2 cells with a concentration of 1 μM ER decreased the BaP-induced DNA migration 
by 50%. Interestingly, one of the ITC constituents of Eruca sativa, identified as erysolin, showed 
stronger activity compared to ER by inhibiting CYP1A1 activity in BaP-treated HepG2 cells by 50% 
at lower concentrations (5 μM) [77]. Despite the evidence from cell models, ER administered to rats at 
a dose of 3mg/kg day, corresponding approximately to human dietary intake, was able to only increase 
CYP1A1 in the lung and CYPB1B1 in both liver and lung tissue [57]. However, in the same study the 
correlation between the protective effects against chemically induced mutagenesis and the decrease of 
the formation of active mutagen intermediates by ER was demonstrated. Similarly, the bioactivation of 
a chemical carcinogen, 2-amino-3-methylimidazo-(4,5-f)quinoline (IQ), in ER pre-treated rats, was 
clearly decreased after ER pre-treatment, as previously shown following treatment with the structurally 
related ITC, SF [57,70].  
These findings obtained in animal systems have been subsequently confirmed in human tissues. 
Hanlon and colleagues [57] studied the modulation of CYP450 enzymes expression and activity in 
human tissues after treatment of human liver slices with ER. CYP450-mediated dealkylations were not 
inhibited  following  ER  treatment,  with  the  exception  of  ethoxy-and  methoxyresorufin  slightly 
modulated at the highest concentration (50 µ M). Although CYP1A2 and CYP1B1 apoprotein levels 
were markedly up-regulated by ER at a concentration of 10 µM  in rat liver, a modest increase was Toxins 2010, 2                         
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observed in one of the human tissue samples tested. The observed inhibition of phase I enzymes by 
both ER and SF on rat and human tissues at higher concentrations may be related to the toxicity of 
high ITC concentrations rather than a real effect on phase I enzymes. 
Despite the absence of an effect of ER in reducing phase I enzymes, phase II enzymes seem to be 
modulated similarly to SF by ER. Compared to SF, however, ER is less potent in inducing quinone 
reductase (QR) activity in murine hepatoma cells and both QR and glutathione transferase (GST) 
activities in mouse tissues [56]. This might be due to the difference in side chain length and oxidation 
status of sulphide sulphur between the ITC analogs.  
Interestingly, induction of phase II detoxification enzymes by ITCs reported in rat tissues exhibits 
organ selectivity. ER induced GSTs activity in the urinary bladder and in the forestomach, and QR 
activity in the urinary bladder and in the duodenum. In all other organs studied, such as liver, kidney, 
spleen, lung, heart, glandular stomach, jejunum, ileum, cecum, or colon plus rectum of rats, following 
intake of ER, or as well of SF, there was no effect on QR and GST activities. This observed organ 
selectivity could be explained by their pharmacokinetic properties. Since N-acetylcysteine conjugates 
of  ITCs  are  excreted  via  the  kidney,  and  deconjugated  within  the  urinary  bladder  resulting  in  
re-absorption of free ITCs in the bladder epithelium, the exposure of bladder epithelial cells to the 
ITCs could occur at higher concentration compared to other organs [78,79].  
In a human colon carcinoma model, ER was shown to significantly induce phase II enzymes. Using 
undifferentiated human colonic Caco-2 cells, 20 µ M ER was able to induce mRNA expression of QR 
(fold increase, ER = 11.1; SF = 3.3) and UDP-glucuronosyl transferase (UGT1A1) (fold increase,  
ER = 11.6; SF = 5.3), showing a stronger bioactivity than SF. It is already known that induction of 
phase II enzymes by ITCs is associated with the nuclear factor-E2-related factor 2 (Nrf2)-Kelch-like 
ECH-associated  protein  1  (Keap1)-antioxidant  response  element  (ARE)  signaling  pathway  [36].  
The cis-acting antioxidant response element (ARE 5‟-(G/A)TGA(G/C)nnnGC(G/A)-3‟) is a specific  
DNA-promoter-binding  region,  which  is  found  in  the  5‟-  flanking  region  of  the  phase  II  and 
antioxidant genes [80]. The ARE-driven gene transcription is regulated partially by nuclear factor 
Nrf2, which under normal conditions is sequestered in the cytoplasm by Keap1). In oxidative stress 
conditions or following cellular exposure to certain chemopreventive agents, Nrf2 is dissociated from 
Keap1 and translocated to the nucleus, where it binds to AREs and transactivates phase II detoxifying 
and  antioxidant  genes.  The  Nrf2-Keap1-ARE  signaling  pathway  appears  to  be  modulated  by  ER 
through different kinases, such as phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein 
kinases (MAPKs). Inhibitors of PI3K/Akt and Raf/MEK/ERK pathways decreased ER-induced phase 
II enzyme mRNA in undifferentiated CACO-2 cells [62].  
In a model of lung cancer, both ER and SF were able to induce QR and GST expression and 
activities in rat lung tissue in a dose-dependent manner and with similar potency. QR protein levels 
were increased three-fold in rat lung slices following 24 hours incubations with both dietary ITCs, and 
similarly, but less markedly, GST protein levels were also elevated [58].  
Recently, significant evidence of the inductive effects of ER, and its structurally related analog SF, 
on detoxifying enzymes in human and rat liver have been provided. ER and SF were shown to cause a 
statistically significant induction of QR and GST protein levels and activities in rat liver tissues up to 
50 µM , but higher concentrations returned QR and GST to control levels [59]. SF appeared to be more 
potent than ER. Neither compound had any significant effect in human liver tissues, however, except Toxins 2010, 2                         
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for a modest increase in  NAD(P)H: quinone oxidoreductase-1 (NQO1) protein levels  and in both 
GSTα and GSTµ, but not in GSTπ protein levels, in only one of the two human samples. In particular, 
the induction of GST activities by the two dietary compounds was dependent from the substrates used, 
the 1-chloro-2,4-dinitrobenzene (CDNB) that is associated with a number of cytosolic transferases, the 
7-chloro-4-nitrobenzo-2-oxa-1,3-diazole  (CNBOD)  and  the  1,2-dichloro-4-nitrobenzene  (DCNB), 
substrates for the α- and π-classes, respectively. ER was able to up-regulate GST activity only when 
CDNB and CNBOD, but not DCNB were used. In contrast, SF was effective when all three substrates 
were used. These findings suggested an isoform-specific induction of GSTs expression and activity by 
both ER and SF in liver from rat and human [59].  
In addition to phase I and phase II modulation, several studies suggest that phase III efflux is also 
modulated by ITCs. Phase III detoxification system involves efflux pumps that actively eliminate toxic 
substances  from  inside  cells.  It  has  been  established  that  membrane  proteins,  notably  multidrug 
resistance (MDR), multidrug resistance protein (MRP), and breast cancer resistance protein (BCRP) of 
the ATP binding cassette (ABC) transporter family encoding efflux pumps, play important roles in the 
development of multidrug resistance [81–84]. Amino acid sequence analyses revealed that all these 
multidrug-resistance  proteins  contain  multiple  transmembrane  domains  (TMDs)  and  intracellularly 
localized ATP binding cassette (ABC) [85]. These multiple TMDs form a pore whereby animal cells 
use the intracellularly localized ABC to hydrolyze ATP to provide an energy source to eliminate 
cytotoxic compounds outward and reduce intracellular drug content to a sublethal level. The activities 
of these multidrug transporters can be up-regulated by many extracellular influences. Some of the  
up-regulation mechanisms are somewhat specific to particular drug transporters, but many are general 
and can affect many physiologic pathways [86–88]. Previously, SF was shown to increase MRP2 
mRNA and protein expressions in primary human and rat hepatocytes coordinately with the induction 
of the detoxification enzymes QR and GST [89]. In human colon Caco-2 cells there was also an 
increase in MRP2 expression together with an increase in QR [90] and UGT1A1 [62]. In these cells 
ER (20 µM ) was able to induce the mRNA of MRP2 by 6.7 fold, and with greater potency compared 
to SF (2.2. fold) [62]. ER also increased modestly MRP1 protein expression in hepatic carcinoma 
HepG2 cells at concentrations higher than 10µM , but the same effect was not observed in human 
cancer lung A549 and colon Caco-2 cells [91]. In contrast, MRP1 protein levels were increased by SF 
in a dose-dependent manner in all three cancer cell lines. Moreover, ER induced MRP2 in HepG2 and 
Caco-2 cells, but not in A549 cells, whereas SF was again effective in all three cell lines.  
5.2. Effects of ER on the physiological control of cell proliferation 
Several studies have showed the anti-proliferative activity of ER in different cultured cancer cells, 
providing mechanistic explanations that are in common to other aliphatic ITCs, such as SF, stressing 
the relationship between structure and biological activity of ITC analogs. Induction of cell cycle arrest 
and apoptosis seems to be an important molecular mechanism to explain the chemoprevention by  
ITCs [64,92–97]. The best understanding of how these phytochemicals impact on fundamental cellular 
processes,  including  the  cell  cycle,  will  come  by  understanding  cancer  biology  first.  The  normal 
growth and replication of cells is carefully regulated by several types of genes and factors that control 
their expression. The tumor suppressor protein p53, also known as „„guardian of genome”, plays an Toxins 2010, 2                         
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essential role in the control of cell proliferation. p53 is normally maintained at low levels in unstressed 
mammalian cells, but in response to cellular stress its accumulation in the nucleus of cells promotes its 
activation  and  stabilization  by  molecular  modifications.  The  active  p53  acts  as  regulator  of  the 
expression  of  a  wide  variety  of  genes  involved  in  apoptosis  and  growth  arrest  [98]  (Figure  3). 
Therefore, p53 can inhibit cell cycle by transactivating the Cyclin-Dependent Kinase (CDK) Inhibitor 
p21
WAF1/CIP1 (p21).  
The p21 protein is an inhibitor of CDKs that regulates the cell cycle by inhibiting both the G1-to-S 
and G2-to-mitosis transitions [99]. Recently, our laboratory has demonstrated that ER up regulates in a 
dose-dependent manner the protein expression of p53 and p21 to inhibit the proliferation of human 
lung cancer A549 cells [31]. Compared to SF, ER showed lower potency in inhibiting proliferation of 
A549 cells (ER IC50 = 97.7 µ M; SF IC50 = 82.0 µ M), as well as in modulating p53 and p21 protein 
expression.  Consistent  with  induction  of  apoptosis,  we  also  demonstrated  that  poly  (ADP-ribose) 
polymerase-1  (PARP-1)  cleavage  occurs  after  ER treatment in  A549 cells,  and  similarly  after SF 
treatment, as previously reported [100]. (PARP-1) is a protein involved in DNA repair in response to 
environmental stress. This protein acts by releasing apoptosis inducing factor (AIC) causing cell death, 
and its inactivation by proteolytic cleavage serves as marker of cells undergoing apoptosis. It was 
recently demonstrated that two ITCs, isolated in daykon sprouts (Raphanus sativus L.), also belonging 
to the family of Brassicaceae, are able to induce a strong cleavage of PARP-1 on human colon cancer 
cells [101,102]. SF and ER are saturated homologues of these ITCs, suggesting that PARP-1 cleavage 
is a mechanism for inducing apoptosis in a variety of cell tissues. 
Figure  3.  The  tumor  suppressor  proteins  p53  and  p21  play  a  key  role  in  the  cellular 
response to DNA damage. Activation of p53 can lead to apoptosis in case of unrepaired 
DNA damage, or indirectly to the block of cell cycle progression by transactivating p21, a 
CDK inhibitor.  
 
 
Previous studies have demonstrated the antiproliferative effects of ER in other cancer cell lines. The 
in vitro studies carried out by Fimognari and colleagues have provided evidence that ER is able to 
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peripheral T lymphocytes [32]. Moreover, cell cycle arrest in the G2/M phase and apoptosis induction 
by ER has been demonstrated in Caco-2 cells [62]. The percentage of Caco-2 cells in the G2/M phase 
was significantly increased following ER treatment compared to untreated cells that were mainly in the 
G0/G1  (56.4%)  and  in  the  S  phase.  The  G2/M  phase  accumulation  was  accompanied  by  a 
corresponding decrease in G1 phase of the cell cycle. At higher ER concentration (50 µ M), cell cycle 
distribution profiles reverted to those of control cells and a significant increase of sub-G1 apoptotic 
cells was observed. The percentage of apoptotic cells and necrotic cells after treatment with ER was 
also increased in a dose-dependent manner, showing the correlation between the reduction of Caco-2 
cell survival and apoptosis induction [62].  
Anti-proliferative effects of ER have also been observed in myeloid leukemia HL60 cells and its 
multidrug-resistant HL60/ADR and HL60/VCR sublines, with IC50 values of 1.9, 5.6 and 7.6 µM , 
respectively [64]. ER was able to induce a statistically significant increase of cells in the G2/M phase 
in both parental HL60 cells and multidrug-resistant HL60/ADR and HL60/VDR cell lines. Moreover, 
ER induced apoptosis and mitochondrial potential dissipation in these human cell lines, and was more 
effective than other aliphatic ITC analogs, such as iberin (IB) and SF [64].  
Recently,  Lamy  and  colleagues  have  reported  the  potential  chemopreventive  activity  of  ER  in 
human hepatic cancer cells, and they have also correlated the significant bioactivity of this dietary 
compound with its in vitro biodegradation kinetics [54]. In HepG2 cells, ER is not detectable in the 
medium after 24 hours and only 25% is found after six hours. Similarly the degradation of ER in 
distilled water is time-dependent with a decrease of its starting concentration of 40%, 70% and 75% 
after one, six and 24 hours, respectively. Despite its degradation kinetics due to being volatile, ER was 
able to reduce HepG2 cell growth in a dose-dependent manner by inducing apoptosis already after  
6 hours and cell cycle arrest at the G2/M phase, as well as increase p53 protein expression followed by 
an increase in p21 protein level. This suggests either that the short-term presence of ER is sufficient to 
elicit  an  effect,  or  alternatively  that  a  proportion  of  ER  binds  to  proteins  in  the  medium  thereby 
allowing for activation of downstream targets. 
5.3. Effects of ER trough ROS-mediated mechanisms 
Oxidative stress, resulting in excessive levels of free radicals and reactive oxygen species (ROS), is 
involved  in  the  pathogenesis  of chronic disease, and may  be  reduced  by improving physiological 
antioxidant defenses through dietary interventions [103]. Rocket salad species have been considered a 
good  dietary  source  of  antioxidant  compounds  [29,30].  ER  is  characterized  by  direct  antioxidant 
activity, because it is able to react with hydrogen peroxide and alkylhydroperoxides to form water and 
an  alcohol  [30,50],  but  also  by  indirect  antioxidant  capacity,  being  a  potent  inducer  of  cellular 
antioxidant systems, like the thioredoxin reductase 1 (TrxR1), as demonstrated in human breast cancer 
MCF-7 cells [60]. Recent work has correlated the pro-oxidant capacity of ITCs associated with ROS 
production with their chemopreventive properties [104]. It has been suggested that PEITC selectively 
killed transformed cells by increasing ROS production, because transformed cells have a higher level 
of ROS than non-transformed cells, and the further increase of ROS induced by PEITC treatment led 
to cell cycle arrest and apoptosis thereby preventing cancer cell proliferation [66]. ER also improved 
the cytotoxic  effects of the arsenic trioxide (ATO), therapeutically used in the treatment of acute Toxins 2010, 2                         
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promyelocytic leukaemia (APL) through a ROS-dependent mechanism. In combination with ATO, ER 
may represent a promising therapeutic approach, by significantly increasing ATO-induced cytotoxicity 
in human leukaemia cells, acute myeloid leukaemia (HL-60) and erythroblastic chronic myelogenous 
leukemia (K562) cells, but not in promonocytic leukemia (U937) cells, through a ROS-dependent 
mechanism [105]. However, the ATO-induced cytotoxicity by ER was variable compared to erysolin 
and SF that significantly enhanced the growth inhibitory effects of ATO in all three leukemic cells 
lines, and for this reason ER was not subjected to further study [105]. 
5.4. Down-regulation of androgen receptor (AR) signaling pathway as novel mechanism of 
chemoprevention by ER 
Androgen receptor (AR) is the most relevant signaling pathway in prostate cancer, and is presently 
considered a significant drug target, since its inhibition has demonstrated to be important for prostate 
cancer  prevention  and  treatment  [106–108].  Recent  work  suggests  that  increased  consumption  of 
broccoli  and  other  cruciferous  vegetables  may  have  a  significant  benefit  in  reducing  prostate  
cancer [3–5,109,110]. The protective effects of cruciferous vegetables consumption against prostate 
cancer appears to be partially related to the potential ability of ITCs to interact with the AR signaling 
pathway. PEITC perturbs AR signaling pathway by down regulating AR transcription through the 
inhibition  of  the  AR  gene  promoter  (Sp1)  expression  and  inducing  AR  protein  degradation  in 
androgen-dependent (AD) and androgen-independent (AI) prostate cancer LNCaP cells [111]. These 
findings were supported by further observations that PEITC inhibited IL-6-induced AR-activation in 
androgen sensitive prostate cells [112]. Recently several in vitro studies also demonstrated that SF 
interacts with the AR pathway reducing prostate cancer survival [63,113]. Gibbs and colleagues have 
reported that SF treatment reduced protein levels of AR and its target genes, such as the prostate-specific 
antigen (PSA), by hyperacetylation of HSP90 in LNCaP cells [113]. SF treatment also decreased AR 
mRNA and protein levels, PSA secretion, and AR promoter activity in both LNCaP and C4-2 prostate 
cells [63]. A similar effects appears to be shared by naturally occurring thio analogs of SF, whereas 
sulfonyl analogs were inactive [63]. ER (0–10 µ M) was also able to induce a statistically significant 
decrease in the expression of AR and PSA proteins in LNCaP cells [63].  
6. Conclusions and Remarks 
Pharmaceutical discovery of novel drugs for chronic diseases has turned many times to the plant 
world  to  identify  promising  bioactive  phytochemicals.  Epidemiological  evidence  and  subsequent 
studies using cell and animal models have identified cruciferous vegetables as important sources of 
such phytochemicals that are emerging as novel potential anticancer agents. Although a lot of research 
has focused mainly on sulforaphane, derived from broccoli, and PEITC, derived from watercress, other 
ITCs such as ER are promising. In particular, there is evidence that ER is selective in its effects, 
inducing a strong antiproliferative effect on some human cancer cells, but not in non-transformed cells. 
This selectivity is an important characteristic that requires further investigation to identify amongst 
other things whether certain ITCs are selective on certain cancers. Although cell and animal models 
are essential tools to understand effects on and mechanisms of chemoprevention, it is important to 
direct research focus towards human intervention studies, using either isolated ITCs or whole foods, Toxins 2010, 2                         
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and discover whether the same mechanisms are also occurring in humans or whether food-derived 
compounds are working in a completely different way. 
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